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Abstract
Hemangiopericytoma (HPC) is an exceedingly rare tumor of uncertain malignant potential. Approximately 300
cases of HPC have been reported since Stout and Murray described HPCs as “vascular tumors arising from Zimmer-
man’s pericytes” in 1942. After further characterization, the WHO reclassified HPC as a fibroblastic/myofibroblastic
tumor. Long term follow up is mandatory because the histologic criteria for prediction of biologic behavior are
imprecise. There are reports of recurrence and metastasis many years after radical resection. The head and neck
incidence is less than 20%, mostly in adults.
We report herein a case of HPC resected from the neck of a 74-year-old woman, who presented in our depart-
ment with a painless right-sided neck mass. The mass was well circumscribed, mobile and soft during the palpa-
tion. The skin over the tumor was intact and normal. Clinical diagnosis at this time was lipoma. A neck computer
tomography scan showed a large submucosal mass in the neck, which extended in the muscular sites. The tumor
was completely removed by wide surgical resection. During surgery we found a highly vascularised tumor. The
histopathologic examination revealed a cellular, highly vascularized tumor. The diagnosis was that of solitary fibrous
tumor, cellular variant, with haemangiopericytoma-like features. The patient had normal postoperative course of
healing and 24 months later she remains asymptomatic, without signs of recurrence or metastases.
Introduction
Solitary fibrous tumor was first described by Wagner in
1870 [1]. It develops from the cells lining capillaries,
pericytes which are small, oval or spindle-shaped cells
lining capillaries [2]. They were first described in 1923
by Zimmermann, as specialized cells normally present
around amphibian and vertebrate capillaries; they were
thought to be modified smooth-muscle cells [3].
Discussion
Epidemiology
In 1942 Stout and Murray described nine tumors which
were composed of capillary blood vessels with one or
more layers of rounded cells arranged about them
which cannot be called glomus tumors and suggested
hemangiopericytoma (HPC) as properly descriptive
name [4]. Two of the described tumors originated in
head and neck sites (infraorbital and auricular). In 1949,
Stout expanded on his previous work by better delineat-
ing the histological details of 25 cases of hemangioperi-
cytoma submitted to him from medical centers around
the country. Two of these originated in the head and
neck; the first reported case was of nasal HPC, another
was in the tongue base [5,6]. Since then, only approxi-
mately 300 cases of HPCs have been mentioned in the
literature [7].
Over the years, it appeared that this growth pattern was
an o n - s p e c i f i co n e ,s h a r e db yn u m e r o u s ,u n r e l a t e d
benign and malignant lesions, and that HPC was better
considered as a diagnosis of exclusion. Three categories
of lesion may now be individualized within the heteroge-
neous group of HPC like neoplasms. The first category
corresponds to those non-HPC neoplasms that occasion-
ally display HPC-like features (e.g. synovial sarcoma).
Lesions belonging to the second category show clear evi-
dence of myoid/pericytic differentiation and correspond
to true HPCs. They generally show a benign clinical
course, and include glomangiopericytoma/myopericy-
toma, infantile myofibromatosis (previously called infan-
tile HPC), and a subset of sinonasal HPCs. The third
category is the solitary fibrous tumor (SFT) lesional
group, which includes fibrous-to-cellular SFTs, and
related lesions such as giant cell angiofibromas and lipo-
matous HPCs. In practice, any HPC-like lesion can be
allocated to one of these categories, leaving the ill-defined
‘haemangiopericytoma’ category empty [3].
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presentation and on histological examination. Thereby
we may have a tumor with aggressive clinical presenta-
tion, with metastases and increased mitotic activity on
the histopathological examination or we may have a
tumor with a relatively benign behavior, which increases
only locally, without giving metastases [8].
Cellular SFT is uncommon mesenchymal tumor,
accounting for 1% of all blood vessel-related neoplasms
and less than 3-5% of all soft tissue sarcomas [9].
Such a tumor can occur in any site throughout the
human body, since there are everywhere capillaries and
they have pericytes. Enzinger and Smith [10] evaluated
106 solitary fibrous tumors and concluded that the com-
monest site is lower extremity (35%) followed by pelvis or
retroperitoneum (25%), trunk (14%) and upper extremity
(10%). It has also been described occurring in the brain
and spine, oesophagus, breast and lung. Comparing the
few clinical observations, that exist, the frequency of
occurrence in the head and neck is estimated between
16% and 33% of all cellular SFTs occurring in various loca-
lizations [11]. In the head and neck region it has been
described in the orbit, nasal cavity, oral cavity, jaw, parotid
gland, parapharyngeal space, masticator space, jugular
foramen, etc. [12]. Cellular SFT may occur in all age
groups, predominantly in the 6
th and 7
th decades, with no
sex predilection. The etiology is unknown, although the
presence of cellular SFT has been linked to trauma, pro-
longed steroid use and hormonal imbalance [13].
Clinical features
Clinically, the cellular SFT usually presents as a painless
enlarging mass [2], symptoms being mostly due to pres-
sure on adjacent structures [12]. Various paraneoplastic
syndromes have been described in association with cel-
lular SFT, including hypoglycemia, hypophosphatemic
osteomalacia and hypertrophic pulmonary osteoarthro-
pathy [14].
Histopathological features
Cellular forms of SFT resemble what had been called
HPC prior to 1990. Usually they have a monotonous
appearance, even, moderate to high cellularity, little
intervening fibrosis, numerous thin-walled ‘stag horn’
branching vessels, and round-to-oval monomorphic
tumor cell nuclei [15,16]. Immunohistochemically, tend
to be less frequently positive for CD34 than fibrous
SFT; when positive, the staining is usually less strong
than in fibrous SFT and often focal [3]. Criteria of
malignancy for SFT include large tumor size (> 50 mm),
disseminated disease at presentation, infiltrative margins,
high cellularity, nuclear pleomorphism, areas of tumor
necrosis and an increased mitotic index (> 4 mitoses per
10 high-power fields (HPF) [17].
Diferential diagnosis
Diagnosis of highly vascularized tumors in the head and
neck is challenging, especially because of the difficulty
in differentiating cellular SFTs from other tumors that
have prominent vascularization: schwannoma, myofibro-
blastoma, metastasis from spindle-cell carcinoma, low-
grade fibromyxoid sarcoma (especially if myxoid foci are
prominent), synovial sarcoma, and malignant peripheral
nerve sheath tumor [3]. Angiographic features may help
in differentiating cellular SFTs from other hypervascular
lesions. Tomography, radiography and angiography are
not specific and magnetic resonance imaging reveals a
solid mass with isodense contrast in T1 [7].
Treatment and prognosis
Survival is correlated with the grade, size, and margin sta-
tus [17]. Previous reports have examined the effect of
grade on the prognosis of patients with cellular forms of
SFTs occurring at different sites throughout the body.
Enzinger and Smith [10] had analyzed 106 cases of cellu-
lar SFTs. In one of their reports, 16% of patients had
lesions in the head and neck region, and overall survival
was 70%. The authors defined a lesion as high grade if it
demonstrated more than four mitotic figures per 10
high-power fields, or displayed increased cellularity or
necrosis. In tumors with more than four mitotic figures
per 10 high-power fields, 10-year overall survival was
29%. In contrast, patients whose tumors demonstrated
four or fewer mitotic figures per high-power field had a
10-year overall survival of 77%. Similarly, worse survival
was demonstrated for patients with tumors showing
evidence of necrosis and tumors greater than 6.5 cm in
diameter [10]. Other investigators, however, have not
been able to demonstrate this relationship between mito-
tic activity and survival [18]. The rate of metastases from
cellular SFT is low, and most patients do not develop
local recurrences. However, in an analysis of 45 cases of
cellular SFT of the head and neck reported in the litera-
ture, 40% were locally recurrent and 10% showed distant
metastases [19]. Metastases are known to occur to the
lung, bone, liver, regional lymph nodes and pancreas
[20]. Recurrences can often be long delayed. In Enzinger’s
report, 7 of 16 patients had recurrence after a disease-free
interval of 3 years. The recent experience reported from
the Memorial Sloan-Kettering Cancer Center found a
93% and 80% 2 and 5-year survival rate, respectively, for
classic cellular SFT, but made no mention if histologically
malignant tumors were included [21]. The above under-
score the need for close long-term follow-up in all
patients with cellular SFT-even those with histological
low-grade tumors-but paying particular attention to
those lesions that have recurred and/or are high-grade
lesions on pathological review. Follow-up examination of
recurrent lesions should include a chest radiograph.
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tion is wide surgical resection, if it is possible. The use-
fulness of adjuvant radiation therapy has not been fully
supported in the literature, although more recent studies
s u g g e s tt h a tr a d i a t i o nt h e r a p yc a nb eu s e di ns o m e
situations [5]. In particular, postoperative radiation ther-
apy has been recommended in cases of incomplete
surgical removal. The role of chemotherapy in the treat-
ment of cellular SFT has not been clearly determined.
Another study from the Memorial Sloan-Kettering
Cancer Center found cellular SFT to be responsive to
chemotherapy [22]. In particular, adriamycin used alone
or in combination was most effective in producing com-
plete and partial remissions in 50% of their cases.
Chemotherapy can be useful for preoperative tumor
reduction as a postoperative adjunct for tumor metas-
tases and for palliation of locally nonoperative lesions
[23]. Perioperative embolization has been suggested as
an adjuvant for decreasing tumor vascularity and size
[24]. A study by Craven [24] encouraged the use of rou-
tine angiography and perioperative embolization to
reduce intraoperative hemorrhage. They point to earlier
reports where significant hemorrhage and even exangui-
nation occurred.
Case report
A 74-year-old female patient presented in our depart-
ment with a large right-sided neck mass. The mass was
painless, well circumscribed, relatively mobile and soft
during the palpation. The skin over the tumor was
intact and normal [Fig. 1]. As the patient herself men-
tioned, the tumor occurred 10 years ago and was
increasing gradually. In our case, matches the age and
the clinical presentation, as they are described in the lit-
erature, but, from our patient’s background, there was
not anything relevant with the etiology of the tumor’s
growth, namely, it was not mentioned trauma in the
tumor’s region nor prolonged steroid use or hormonal
imbalance. The reason she came for removal was the
aesthetical appearance. Clinical diagnosis at this time
was lipoma. A computer tomography scan showed a
large submucosal mass in the neck, 8-9 cm in greatest
diameter, extending to the muscular sites [Fig. 2]. Dur-
ing surgery under general anaesthesia, it was found that
there was not a lipoma, but a sarcomatous tumor with a
high vascularisation. The intervention of removal was
very earnest, with a big hemorrhage (it was required a
blood transfusion of 4 units) [Fig. 3].
Gross examination of the surgical specimen showed
a well circumscribed mass with a greatest diameter of
9 cm. Cut surface was yellowish and spongy in
appearance.
Microscopy revealed a cellular, highly vascularized
neoplasm. The neoplastic cells were closely packed,
round or spindle shaped, with scanty cytoplasm and
vesicular nuclei, showing little or no pleomorphism.
Mitoses rarely exceeded 3 per 10 high-power fields. The
vessels were variably ectatic, mostly thin walled and
branching. There were also little intervening fibrosis and
Figure 1 The patient before surgery. A 74-year-old female patient
presented with a large right-sided neck mass. The skin over the
tumor was intact and normal.
Figure 2 Computer Tomography scan. A computer tomography
scan showed a large submucosal mass in the neck, 8-9 cm in
greatest diameter, extending to the muscular sites.
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cells and foamy macrophages [Fig. 4, 5, 6].
On immunohistochemical grounds the tumor cells
were positive for CD99, CD34 and vimentin and nega-
tive for smooth muscle actin, desmin, S-100 and CD31.
Ki-67 was < 2% [Fig. 7].
The diagnosis was that of solitary fibrous tumor, cellu-
lar variant, with haemangiopericytoma-like features.
Our case confirms that the therapeutical standard of cel-
lular SFT is the radical resection and that there is a severe
difficulty in the intervention, because of the tumor’sh i g h
vascularisation and tendency to bleed. The tumor was
completely removed by wide surgical resection and our
patient had a normal postoperative course without signs
of recurrence or metastases, two years later [Fig. 8].
Conclusions
Cellular variant of SFT is a very rare slow-growing vas-
cular tumor with a variable malignant potential and the
biological behavior is difficult to predict. Recommended
Figure 3 Surgical resection. The spindle-shaped incision during
surgical resection of the tumor.
Figure 4 Histopathological examination. Histopathological
examination of the surgical specimen revealed the presence of
solitary fibrous tumor, cellular variant, with haemangiopericytoma-
like features (Haematoxilin and Eosin, magnification × 100).
Figure 5 Histopathological examination. Monomorphic tumor
cells arranged around thin-walled vessels (Hematoxilin and Eosin,
magnification × 200).
Figure 6 Histopathological examination. Masson trichrone stain
× 100 - scanty fibrosis.
Figure 7 Histopathological examination. CD34 immunohisto-
chemical stain: strong positinity of tumor cells.
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up is necessary in patients even after radical resection
because recurrence or metastases may be delayed by
many years. Adjuvant radiotherapy and chemotherapy
can cause tumor regression and are not suggested as
primary treatment.
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Figure 8 After surgery. The patient after surgery.
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